Invest in ME Conference 12: First Class in Every Way
OverTheHills wraps up our series of articles on this year's 12th Invest in ME International Conference (IIMEC12) in London with some reflections on her experience as a patient attending the conference for the first time.
Discuss the article on the Forums.

Ruxolitinib (JAK1 JAK2 inhibitor): remarking results on intestinal inflammation

Discussion in 'Other Health News and Research' started by Aubry, Nov 2, 2017.

  1. Aubry

    Aubry Senior Member

    Messages:
    137
    Likes:
    159
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854652/#!po=31.3333

    C respresents inflamed dentric cells of the gut before and after administration of Ruxolitinib (the purple grapes are inflamed cells). This is causing probably the abnormalities seen in the micro biome of all ME/CFS patients.Since the micro biome is more and more investigated this could be very interesting for ME/CFS as well. Prof. Meirleir will start trials in 2018 with Filgotinib (another JAK inhibitor) in his patient groups.


    Skin and intestinal GvHD responds to ruxolitinib
    [​IMG]
     

    Attached Files:

    • C.jpg
      C.jpg
      File size:
      72.7 KB
      Views:
      1
    Twazzle, unicorn7, ErdemX and 4 others like this.
  2. knackers323

    knackers323 Senior Member

    Messages:
    1,384
    Likes:
    406
    This looks good. Following
     
  3. jaybee00

    jaybee00 Senior Member

    Messages:
    105
    Likes:
    125

See more popular forum discussions.

Share This Page